

The Latest Biologic Advances in Psoriasis

A CME Lunch Symposium

in conjunction with the

GSD 53RD ANNUAL MEETING

Saturday, May 31, 2008

1:00 - 2:00 p.m.

Sapelo Room, The Cloister



AGENDA

1:00 - 1:05 pm Welcome and Introduction

1:05 - 1:35 pm Lecture and Lunch

What's on the Horizon for New Agents in the Treatment of Psoriasis?

1:35 - 2:00 pm Questions and Answers

Faculty

Theodore Rosen, MD

*Professor of Dermatology
Baylor College of Medicine
Houston, Texas*

Target Audience

This educational activity has been developed to meet the educational needs of clinical dermatologists and dermatology professionals who wish to expand their knowledge of psoriatic diseases.

Sponsored by:
**University of Nevada
School of Medicine**

Learning Objectives

Following completion of this activity, participants should be able to:

- Review emerging clinical trial data on the biologic treatments of moderate-to-severe psoriasis
- Summarize the potential implications of the most recent findings on the biologic treatment of psoriasis
- Discuss the new clinical trial data on monoclonal antibodies targeted toward the IL-12/ IL-23 blockade in psoriasis

CME Accreditation and Designation

The University of Nevada School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The University of Nevada School of Medicine designates this educational activity for a maximum of *1.0 AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pre-register now as space is limited.

To attend this lunch symposium, RSVP to maryann@theassociationcompany.com

Visit www.gaderm.org or contact Maryann McGrail with questions at maryann@theassociationcompany.com or 404-310-5866